Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Resveratrol + delta-tocotrienol (TRM) is a nutritional supplement combination being investigated for the management of metabolic syndrome and type 2 diabetes. The formulation typically consists of 250 mg of delta-tocotrienol, often sourced from annatto-derived DeltaGold, and 150 mg of resveratrol. The combination exerts antioxidant and anti-inflammatory effects and has been shown in clinical trials to modulate the expression of specific microRNAs, including the upregulation of miR-130b-5p and miR-221-5p and the downregulation of miR-122-5p. These molecular changes are associated with improvements in central obesity, insulin resistance, and dyslipidemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on resveratrol + delta-tocotrienol.